Paul Tudor’s major investments are in global macro positions and his funds Tudor BVI Global manage in excess of $16 billion. The equities portfolio disclosed however is only worth $4 billion. Tudor Investment has more than 1000 equity positions disclosed publicly, the portfolio is highly diversified with very few major stakes.
Paul Tudor Buys Pfizer, Agilent, Cytec
Tudor Investment bought more than 300 new positions in the last quarter, the few notable buys of the fund were:
Tudor Investment bought 1.82 million shares of Pfizer Inc. (NYSE:PFE) in Q1, making it the second largest position. The fund also bought 550,000 shares of Agilent Technologies Inc. (NYSE:A), now sixth largest position and also bought 77,300 shares of Biogen Idec Inc. (NASDAQ:BIIB) which is now the fund’s 10th largest position.
The fund also bought Cytec Industries Inc (NYSE:CYT), Mead Johnson Nutrition CO (NYSE:MJN) and ENSCO PLC (NYSE:ESV). Cytec Industries Inc (NYSE:CYT), a chemicals company, has been repeatedly pitched by John Burbank in his presentations and letters. The fund is very bullish on the company and holds it as its largest holding with ownership in 3.52 million shares.
Sells Apple, Vodafone, MetroPCS, Zynga
Paul Tudor’s fund sold 386,124 shares of Apple Inc. (NASDAQ:AAPL), thus exiting the investment. Other holdings that were closed in Q1 were Vodafone Group Plc (NASDAQ:VOD), Abercrombie & Fitch Co. (NYSE:ANF) and Lowe’s Companies, Inc. (NYSE:LOW). Tudor Investment also sold out smaller positions in Johnson & Johnson (NYSE:JNJ), MetroPCS Communications. The fund sold 2.37 million shares of Zynga Inc (NASDAQ:ZNGA) in Q1.
Increased WellPoint, Coca-Cola, Merck
Tudor Investment increased holding in several companies in Q1, the major additions were in Covidien plc (NYSE:COV), AbbVie Inc (NYSE:ABBV) and WellPoint, Inc. (NYSE:WLP).
The fund also increased positionsin The Coca-Cola Company (NYSE:KO) by 2500 percent. Tudor now holds 200,000 shares of the beverage manufacturer. Other significantly increased positions were Amgen, Inc. (NASDAQ:AMGN), Merck & Co., Inc. (NYSE:MRK) and HCA Holdings Inc (NYSE:HCA).